Background: Psoriasis is a cutaneous inflammatory condition characterized by an altered
turnover of keratinocytes leading to scaly patches. Secukinumab and ixekizumab are two biologic
drugs inhibiting interleukin-17.
Objective: We report the first case, according to Naranjo score, of a secukinumab-induced erectile
dysfunction with severe plaque psoriasis that disappeared after switching to another anti IL17 drug
Methods: A 45 years old man experienced erectile dysfunction during treatment with an anti-IL17.
The adverse effect appeared after 60 days of treatment with secukinumab and rapidly disappeared after
discontinuation of the drug. All necessary urologic exams were carried out. Re-administration of
secukinumab, due to the exacerbation of psoriasis, caused the same sexual dysfunction after 60 days.
Results: Switching to ixekizumab lead to a resolution of the erectile dysfunction and a complete
Conclusion: We describe for the first time a sexual dysfunction possibly due to secukinumab and
its resolution after the switch to another similar but different drug, highlighting the potential difference
between anti-IL17A drugs.